Close Menu
    What's Hot

    Felicitysolar Supports Safer and More Sustainable Campus Lighting at Yobe State University in Nigeria

    May 27, 2026

    Enlit Africa 2026: Huawei Launches Intelligent Substation Solution for Sub-Saharan Africa

    May 27, 2026

    Fastmarkets convenes global critical minerals leaders as markets move to the center of national security and industrial policy

    May 27, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Felicitysolar Supports Safer and More Sustainable Campus Lighting at Yobe State University in Nigeria
    • Enlit Africa 2026: Huawei Launches Intelligent Substation Solution for Sub-Saharan Africa
    • Fastmarkets convenes global critical minerals leaders as markets move to the center of national security and industrial policy
    • Casio to Release MR-G Inspired by the Polar Brinicle Phenomenon
    • Univar Solutions Strengthens Strategic Partnership with Dow for Silicone Additives in EMEA
    • Venus Medtech Hosts Inaugural Global Partner Summit in Paris
    • Huawei Hosts 3rd Global C&I Visionaries Summit, Shaping a Greener Future Across Diverse Industries
    • QIA Anchors Public Power Corporation’s Share Capital Increase
    • Home
    • Contact Us
    Cairo GuardianCairo Guardian
    Wednesday, May 27
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Cairo GuardianCairo Guardian
    Home » Innovative experimental malaria drug based on antibodies discovered

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022 Featured News
    Share
    Facebook Twitter LinkedIn Pinterest Email

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Keep Reading

    Plekhanov University in Dubai Inaugurates R&D Center and Unveils New Patent and Two Revolutionary AI Technologies

    Thumbay Group Breaks Ground on the Region’s First Private, Fully Integrated Psychiatric and Rehabilitation Hospital at Sharjah Healthcare City

    Asana Names Washmen, a Cloudfresh Customer, the ‘AI Breakthrough’ in EMEA at the 2026 Work Innovation Awards

    High-End Smart NEV Brand VOYAH Advances Global Layout with Multidimensional Efforts; VOYAH Taishan X8 Draws Widespread Attention

    AI Match Predictions, Live Table Projections, and More: Tribuna.com Releases Full Feature Breakdown for the 2026 FIFA World Cup

    Bitget Launches New Pre-IPO Product With SpaceX as First Listing

    Latest News

    Measles outbreak in Bangladesh passes 60,000 cases

    May 23, 2026

    UAE and Germany review strategic ties in Berlin

    May 21, 2026

    PM Modi and Meloni spotlight deepening India-Italy ties

    May 21, 2026

    South Korea launches $665.5 million industrial growth fund

    May 20, 2026

    Japan and South Korea launch energy security framework

    May 20, 2026

    Etihad expands Paris route with double daily A380 flights

    May 20, 2026

    GME posts strongest trading week in two decades

    May 19, 2026

    Porsche reveals bespoke 911 GT3 RS in Macadamiametallic

    May 18, 2026
    © 2026 Cairo Guardian | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.